IFNA1 and Miyoshi myopathy: Pegylated interferon-α (IFNα), as studied in the European Organisation for Research and Treatment of Cancer (EORTC) 18991 trial, in patients with stage III MM significantly reduced the risk of relapse (HR 0.87), however showed no impact on overall survival [373].